Having trouble accessing articles? Reset your cache.

Amitiza lubiprostone: Interim Phase III data

Interim data from a 48-week, open-label, Japanese Phase III safety trial in 209 CIC patients showed that 24 µg

Read the full 191 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE